Acetyl-L-Carnitine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Short Review

CNS Drugs

Volumn 21, Issue , 2007, Pages 39-43

  De Grandis, Domenico ^a  

^a Ospedale Civile di Rovigo   (Italy)

Author keywords

Acetyl Ester; Dorsal Root Ganglion Cell; Oxaliplatin; Paclitaxel; Vinca Alkaloid

Indexed keywords

CISPLATIN; LEVACECARNINE; PACLITAXEL; ACETYLCARNITINE; ANTINEOPLASTIC AGENT; NOOTROPIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CLINICAL FEATURE; HUMAN; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; PERIPHERAL NEUROPATHY;

ACETYLCARNITINE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NOOTROPIC AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 35348914748     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200721001-00006     Document Type: Review

References (33)

1. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006 Mar; 72(3): 151–69
2. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003; 63(15): 1549–63
3. Bacon M, James K, Zee B. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer 2003 Jul–Aug; 13(4): 428–34
4. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 1992 May; 10(5): 718–26
5. Marrs J, Newton S. Updating your peripheral neuropathy “know-how”. Clin J Oncol Nurs 2003; 7: 299–303
6. Vinorelbine treatment [package insert]. Irvine (CA): Gensia Sicor Pharmaceuticals Inc., 2002
7. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004 Nov 17; 96(22): 1682–91
8. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989 Mar; 39(3): 368–73
9. Potter J, Higginson IJ. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. Lung Cancer 2004 Mar; 43(3): 247–57
10. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of taxol. J Nat Cancer Inst Monogr 1993; (15): 107-15
11. Docetaxel. American Hospital Formulary Service (AHFS). Bethesda (MD): American Society of Health-System Pharmacists (ASHP), 2002
12. Posner JB. Neurotoxicity caused by chemotherapeutic agents. In: Dale D, Federman D, editors. Scientific American medicine. New York: WebMD, 2001: Chapter 11, Section 6: 1–14
13. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006; 33: 15–49
14. Cavaletti G, Fabbrica D, Minoia C, et al. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 1998; 9: 443–7
15. Cavaletti G, Tredici G, Marmiroli P, et al. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 1992; 84: 364–71
16. Warner E. Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995; 5: 161–9
17. Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997; 35: 47–53
18. Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004 May; 109(1–2): 132–42
19. Iñiguez C, Larrodé P, Mayordomo JI, et al. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel. Neurology 1998 Sep; 51(3): 868–70
20. Granberg SM, Sonka S, Stevenson LL, et al. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 1989; 25(1): 62–4
21. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990 Sep 15; 66(6): 1117–23
22. Stubblefield MD, Vahdat LT, Balmaceda CM, et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005 Jun; 17(4): 271–6
23. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005 Jan 11; 64(1): 26–31
24. Pisano C, Oratesi G, Vesci L, et al. Acetyl-L-carnitine reduces the taxol-induced neurotoxic effects [abstract]. In: 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam. Clin Cancer Res 2000; 6(11 Suppl.): 4578
25. Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006 Apr 24; 397(3): 219–23
26. Calvani M, Peluso G, Benatti P. Cento anni di carnitina. Le Scienze 2005; 443: 80–8
27. Furlong JH. Acetyl-L-carnitine: metabolism and applications in clinical practice. Alt Med Rev 1996; 1: 85–93
28. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003; 9(15): 5756–67
29. Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005 Jul–Aug; 25(4): 2681–7
30. Chiechio S, Caricasole A, Barletta E, et al. L-Acetylcarnitine induces analgesia by selectively upregulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol 2002 May; 61(5): 989–96
31. Chiechio S, Copani A, De Petris L, et al. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-κB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006 Jun 9; 2: 20. doi:10.1186/1744-8069-2-20 [online]. Available from URL: http://www.molecularpain.com/content/2/1/20 [Accessed 2007 May 17]
32. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005 Mar–Apr; 91(2): 135–8
33. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005 Aug; 41(12): 1746–50